RDIF Builds Sputnik V Vaccine Network in Mexico, Brazil, and India
Posted on 09/16/2020
The Russian Direct Investment Fund (RDIF) and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. According to the press release, “Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India. The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations.”
Earlier on September 11, 2020, RDIF disclosed a cooperation agreement with the State of Bahia (Brazil), through its Health Secretariat, to supply up to 50 million doses of Sputnik V. On September 9, RDIF and the pharmaceutical company Landsteiner Scientific announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico.
